Lymphatic Diseases Clinical Trial
Official title:
Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial
This study aims to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. To study the effects of octreotide, the researchers conducted a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and other lymphatic disorders.
This study aimed to investigate whether octreotide, a medication used off-label to treat chylothorax, has a direct effect on human lymphatic drainage. Chylothorax is a condition in which there is an accumulation of lymphatic fluid in the chest cavity, and the mechanism through which octreotide helps to resolve this condition is not well understood. It has been speculated that the drug may reduce lymph production, but this has not been directly demonstrated. To study the effects of octreotide on human lymphatic vessels, the investigators conducted two experiments: a pre-clinical experiment using human lymphatic vessels mounted in a myograph chamber, and a clinical experiment in which a double-blinded, randomized, cross-over trial was conducted in 16 healthy adults, assessed by using plethysmography and near-infrared fluorescence imaging. The results of the study will be used to determine the role of octreotide in the treatment of chylothorax and to clarify the mechanism through which it acts. It is important to continue researching and developing effective treatments for chylothorax, as it can be a difficult condition to manage and may cause serious complications if left untreated. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02497131 -
Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients
|
Phase 2 | |
Recruiting |
NCT01451502 -
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
|
N/A | |
Active, not recruiting |
NCT03264131 -
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
|
Phase 2 | |
Completed |
NCT03744676 -
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
|
Phase 2 | |
Completed |
NCT02335242 -
Sildenafil for the Treatment of Lymphatic Malformations
|
Phase 2 | |
Completed |
NCT03135535 -
Micro-mobile Foot Compression and Diabetic Foot
|
Phase 2 | |
Active, not recruiting |
NCT05441943 -
Lymphaticovenous Anastomosis as Treatment for Lymphedema
|
N/A | |
Recruiting |
NCT06267807 -
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
|
N/A | |
Withdrawn |
NCT05431179 -
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05731141 -
A Prospective Natural History Study of Lymphatic Anomalies
|
||
Recruiting |
NCT03696784 -
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
|
Phase 1 | |
Completed |
NCT03709407 -
"Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study"
|
N/A | |
Active, not recruiting |
NCT02663297 -
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
|
Phase 1 | |
Completed |
NCT02960841 -
Effectiveness of Intracavitary Manual Lymphatic Drainage
|
Phase 4 | |
Recruiting |
NCT05263583 -
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
|
Phase 2 | |
Terminated |
NCT02499627 -
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
|
Phase 2 | |
Recruiting |
NCT03373019 -
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
Phase 2 | |
Recruiting |
NCT03602157 -
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
|
Phase 1 | |
Recruiting |
NCT02690545 -
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
|
Phase 1/Phase 2 | |
Completed |
NCT02744027 -
Imaging of Lymphatic Anomalies
|
N/A |